Home / 2020 / October / 05

Daily Archives: October 5, 2020

Novavax to Participate in Upcoming Conferences

GAITHERSBURG, Md., Oct. 05, 2020 (GLOBE NEWSWIRE) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in four upcoming investor and industry conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, is expected to be discussed in each conference.

Maryland Life Sciences Bio Innovation Conference
Date: Monday, October 5, 2020
Time: 10:25 -11:25 a.m. ET
Panel title: Discussion on Pandemic & Risk Mitigation: A Focus on Preparation & Resiliency
Three Maryland biotech leaders discuss how to prepare for the unforeseen and what is needed to pivot for the future.
Panelist: John Trizzino, Executive Vice President, Chief Business Officer and Chief Financial Officer
To attend: Click here to register.
Guggenheim First Annual Vaccines and Infectious Diseases Conference
Date: Monday, October 5, 2020
Time: 4:15 – 4:45 p.m. ET
Participation: Fireside chat and investor meetings
Novavax participants: Gregory M. Glenn, M.D., President of Research and Development, and John J. Trizzino, Executive Vice President, Chief Business Officer and Chief Financial Officer
Webcast: A replay of the session will be available within 48 hours through the events page of the Company’s website at ir.novavax.com for 90 days following the event.
Goldman Sachs Virtual Event: Inoculating the RecoveryA Discussion on COVID-19 Vaccines, Treatments, Testing of the Economy
Date: Thursday, October 8, 2020
Time: 12:00 – 12:55 p.m. ET
Panel title: Vaccines – Approaching the Light at the End of the Tunnel
Panelist: Gregory M. Glenn, M.D. President of Research and Development
This event is open to Goldman Sachs clients.
BioHealth Capital Region Forum
Date: Monday, October 19, 2020
Time: 12:45 – 1:30 p.m. ET
Panel title: Strengths of our Region: Combatting Infectious Disease
Panelist: Vivek, Shinde, M.D., Vice President of Clinical Development
To attend: Click here to register.

About NVX-CoV2373

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVX-CoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In the Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a Phase 3 trial in the UK and two ongoing Phase 2 studies that began in August; a Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs. For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

Guardion Provides Update on Strategy, Business Plans and Initiatives

  • Emphasis on Differentiation of Brands and Development and Integration of E-Commerce Platform
  • Further Development of Clinically Supported Nutritional Products and Continued Expansion into International Markets
  • Retention of Corporate Finance Associates to Advise on Strategic Transactions Designed to Accelerate Core Business Expansion

SAN DIEGO, Oct. 05, 2020 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) is providing an update to shareholders with regard to its business plans. In conjunction with Guardion’s emphasis on differentiation of brands and the development and integration of an E-commerce platform, and the further development of clinically supported nutritional products and continued expansion into international markets, the Company has retained the investment banking firm of Corporate Finance Associates (“CFA”) to act as its exclusive financial advisor to assist management and the Board of Directors in the evaluation of strategic transactions and opportunities to enhance shareholder value.

Shortly after recent previously announced changes in senior management, the Board of Directors established a Strategy Committee to work with management and to review the Company’s business initiatives, strategies and opportunities in order to maximize shareholder value.

As part of that review, the Board of Directors also determined that it would augment the Company’s organic growth initiatives with potentially strategic acquisitions to accelerate the development of the Company’s core businesses. CFA has been engaged to assist the Company in evaluating complementary products, technologies and businesses that can contribute positively to the Company’s top-line revenues and EBITDA.

The Company also recently retained CORE IR, a boutique investor and public relations strategic advisory firm, to assist the Company with investor relations, public relations, and shareholder communications services. CORE IR’s priority is to focus on expanding market awareness for Guardion and conveying the Company’s business model and growth strategies to its shareholders and the investment community.

Over the past few months, the Company has been designing and implementing various internal growth strategies which it anticipates, over time, will expand the Company’s business platform, product offerings, market position and financial performance with a view to growing the Company and driving shareholder value.

These initiatives and strategies include:

Portfolio Growth and Brand Focus – Continuing to build out and optimize the Company’s core brands, VectorVision and NutriGuard, with its proprietary product lines, such as Lumega-Z, GlaucoCetin, Immune-SF (formerly acuMMUNE), and the VectorVision CSV-2000

Sales Channel Development:

Expand Current B2B Sales Channel – Continuing its work with world-class clinicians, using translational research to focus on new proprietary nutritional research to create new proprietary nutritional strategies

Direct to Consumer – Develop a digital strategy to include a “direct-to-consumer” (“DTC”) E-Commerce platform, which the Company believes will provide high leverage opportunities for the distribution of its eligible products

International – Continuing to build and grow its business internationally, particularly in the Far East

Evidence-Based Therapies – Continuing to demonstrate, both clinically and scientifically, through sponsored and investigator initiated research, the efficacy of the Company’s condition-specific nutritional therapies

Management Team – Expand and strengthen its management team to include the skills required to execute on the strategies

Robert N. Weingarten, Chairman of the Board of Directors, stated, “The Board of Directors believes that these recently-developed initiatives form a critical component in our plans to develop a solid basis for growth and development in the near term. The retention of CFA to review and advise the Strategy Committee on potential transactions, as well to source additional strategic opportunities, is an important step to facilitate Guardion’s capability to accelerate growth in an accretive manner that would be expected to benefit the Company and its shareholders. In addition, the Company has retained an executive search firm to identify a permanent Chief Executive officer to lead the Company’s business initiatives.”

Dr. David Evans, the Company’s Chief Science Officer and interim President and Chief Executive Officer, stated, “We continue to be very focused on our mission to serve the best interests of our shareholders. The changes in senior management over the past few months, the implementation of new business initiatives and strategies, and now the hiring of CFA and its advisors, are in keeping with our belief that the Company’s current market profile and capitalization do not adequately reflect the full value of our unique and compelling proprietary products and technologies. Additionally, the Company’s strong cash position and the absence of debt on its balance sheet will allow for Guardion to exploit acquisition opportunities that would further leverage our valuable asset base and our reputation for evidence-based technologies in order to enhance the Company’s long-term outlook.”

The Company has not set a timetable for this process and does not intend to disclose developments with respect to this process unless and until the process has been completed, and until it enters into a definitive agreement for a specific material transaction, or as otherwise required by law. The retention of CFA to assist the Company in the exploration and evaluation of strategic transactions or acquisitions may not result in any agreement or transaction and, if completed, any agreement or transaction may not be successful or on attractive terms. In addition, a future transaction may also include a capital raising component to fund expanding business operations and/or to fund acquisitions.

About Guardion Health Sciences, Inc.

Guardion is a specialty health sciences company that develops clinically supported nutritional products, medical foods and medical devices, with an emphasis in the ocular health marketplace. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.

About Corporate Finance Associates

Corporate Finance Associates is one of the largest and most experienced middle-market investment banking firms in the nation. Since 1956, CFA has been advising on merger, acquisition, divestiture and capital formation transactions globally. CFA has over 30 offices in the United States, India, Belgium, Denmark, Ireland, Netherlands, Switzerland and the United Kingdom. Additional information about Corporate Finance Associates may be found on their website at www.cfaw.com.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward- looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. The Company has no commitments with respect to any acquisition or investment. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

CORE IR
Scott Arnold
(516) 222-2560
scotta@coreir.com

Corporate Finance Associates Contact:

Daniel Sirvent Joe Sands
Managing Director Managing Director
949.386.7380 949-457-8990 Ext. 114
dsirvent@cfaw.com jsands@cfaw.com

 

AppTech Announces Digital Banking and Payment Technology Partnership with NEC Payments

CARLSBAD, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) — AppTech Corp. (“AppTech”) (OTC Pink Open Market: APCX), a fintech company, today announces that the company has entered into a strategic partnership with NEC Payments B.S.C(c) (“NECP”). NECP provides digital banking and payment technology solutions to facilitate open-integration between financial institutions and the fintech ecosystem, and to drive the take-up of innovative digital financial services products.

Through the deployment of NECP’s technologies, AppTech will extend its product offering to include flexible, scalable, and secure payment acceptance and issuer payment processing that supports the digitization of business and consumer financial services and the migration of cash and other legacy payment types to distanced and contactless card and real time payment transactions.

NECP will assist AppTech to complete the development of its text payment solution and, to do so, AppTech is licensing its patents to NECP enabling them to customize and provide best-in-class software that complements AppTech’s intellectual property. AppTech will also receive licenses to utilize NECP’s digital banking platform, including exclusivity in the United States for its payment acceptance software.

The integration of AppTech’s merchant services and the secure text payment solution with NECP’s digital account and multi-channel issuer payment processing capabilities will enable an end-to-end payment acceptance and digital banking solution for small to medium-sized enterprises. The integration will also enable AppTech to aggressively target straight-through processing opportunities in the business-to-business payments space and to automate payments and data sharing across multiple points in the supply chain, to eliminate manual administration, and minimize transaction processing time.

As part of the agreement NECP will become AppTech’s single largest shareholder, demonstrating the companies’ commitment to the joint success of this partnership.

Luke D’Angelo, Executive Director, AppTech stated “Our significant equity and cash investment into the partnership with NECP provides AppTech with the clearest and quickest opportunity to bring to market cutting edge technologies and achieve scale and profitability from their rapid adoption.”

Andrew Sims, CEO, NEC Payments said, “NEC Payments is delighted to be joining with AppTech in the United States as a part of our strategic plan to invest in partnerships with customer organizations and develop mutual value. AppTech’s existing intellectual property, merchant services, and marketing capabilities are a great complement to our innovative technologies, and the resulting integration and customizations will enable both of our companies to benefit from dynamic market penetration across multiple segments and distribution models.”

The above terms are subject to the capital requirements contained within the relevant agreements. Complete terms of the strategic partnership are disclosed in AppTech’s related 8K SEC filing.

About NEC Payments

NEC Payments B.S.C(c) is a digital banking and payment technology company based in the Kingdom of Bahrain and licensed and regulated by the Central Bank of Bahrain as an Ancillary Services Provider: Card Processor and Payment Services Provider. The company provides innovative financial technology solutions to power high-performance, flexible and secure payment processing, compliance, and financial control systems that may be securely deployed on the cloud, on-premises, and into hybrid environments to provide flexibility, scalability, redundancy, and to drive rapid growth. The company is a principal member of Mastercard and Visa and is compliant with multiple security and business process standards including PCI-DSS L1 v3.2.1, ISO27001 and ISO9001.

NEC Payments contact:
Duaa Ammar, Digital Marketing Manager
duaa.ammar@necpayments.com
+973 1720 3000

About AppTech

AppTech Corp. is a financial technology company utilizing innovative payment processing technologies to complement its core merchant services capabilities. Its patented and proprietary software for merchant services, text marketing and lead generation are licensable or available through a suite of synergistic offerings. AppTech is developing an enterprise-grade text payment system using the simplicity and familiarity of text messaging with multi-factor authentication to ensure security. AppTech also offers digital marketing, software development, mobile app development, website development, website hosting & comprehensive payment processing for brick-and-mortar operations, e-commerce and ACH. For more information about our company, please visit: www.apptechcorp.com

Forward Looking Statements

This press release contains forward-looking statements that are inherently subject to risks and uncertainties. Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “forecast”, “intend”, “may”, “plan”, “project”, “predict”, “should” and “‘will” and similar expressions as they relate to AppTech are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties concerning the Company. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in methods of marketing, delays in manufacturing or distribution, changes in customer order patterns, changes in customer offering mix, and various other factors beyond the company’s control. Actual events or results may differ materially from those described in this press release due to any of these factors. AppTech is under no obligation to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Media Contact:
(760) 707-5959 X115
media@apptechcorp.com

Investor Relations Contact:
(760) 707-5955
ir@apptechcorp.com

Colliers International appoints new Managing Director for Japan business

— Former CBRE Vice Chairman Yukihiro Ogasawara to accelerate growth of Colliers Japan

TOKYO, Oct. 04, 2020 (GLOBE NEWSWIRE) — Leading global commercial real estate services and investment management firm, Colliers International (NASDAQ and TSX: CIGI) today announced that Yukihiro Ogasawara has been appointed as Managing Director & Chairman | Japan.

Ogasawara joins Colliers Japan from CBRE, where he was Vice Chairman of Capital Markets and led a strategy to advise Japanese capital for investment into regional and global markets.

Ogasawara brings across more than 40 years of expertise in recruiting teams, sourcing domestic and foreign capital; structuring finance deals; and overseeing the acquisition and management of office, hotel, residential and land developments.

Prior to CBRE, he forged an impressive career with Sumitomo Realty & Development Co., Ltd. in both Japan and the United States, serving as General Manager of the International Business Department before transitioning to commercial real estate brokerage at Sumitomo Real Estate Sales and serving on the Board of Directors for Sumitomo Real Estate Investment Advisors Inc.

Based in Tokyo, Ogasawara will be responsible for leading the growth of Colliers business in Japan and will be a member of the Asia Executive Team.

John Kenny, Chief Executive Officer, Asia Pacific, commented: “We are delighted to have Ogasawara-San join us to lead and accelerate the success of our clients and our people in one of the world’s most powerful economies. His experience in Capital Markets will be particularly relevant to our clients in the region and around the world as they seek opportunity in the post-Covid economy.”

“Japan is Colliers’ fastest growing market and Ogasawara’s expertise will continue accelerating our growth, attract market leading talent and new client opportunities, and ensure we lead our industry into the future.”

“The platform for growth in Japan has been well laid for an enterprising leader of Ogasawara’s ability thanks to Katsuji Tokita, who generated exceptional results as the leader of our Japan business for the past four years.”

“We are pleased to confirm that Tokita will continue with Colliers as Managing Director | Major Projects, working closely with Ogasawara to provide real estate services to multi-national corporations throughout Japan.”

“It’s such an exciting time to join Colliers as today’s business climate revolutionises the services and solutions our clients need. I am thrilled to lead such an enterprising organisation that matches the pace of Japan’s dynamic and growing market,” said Yukihiro Ogasawara. “I look forward to working with the exceptional team in place and building on our strong track record of success to drive our business forward in the months and years to come.”

Colliers in Japan has over 60 professionals located in Tokyo and Osaka, where they provide investment sales, lease brokerage, valuations, workplace consultancy, design services and property and project management to domestic and international investors, occupiers and developers of real estate.

About Colliers International 
Colliers International (NASDAQ, TSX: CIGI) is a leading real estate professional services and investment management company. With operations in 68 countries, our more than 15,000 enterprising professionals work collaboratively to provide expert advice to maximize the value of property for real estate occupiers, owners and investors. For more than 25 years, our experienced leadership, owning approximately 40% of our equity, has delivered compound annual investment returns of almost 20% for shareholders. In 2019, corporate revenues were more than $3.0 billion ($3.5 billion including affiliates), with $33 billion of assets under management in our investment management segment. Learn more about how we accelerate success at corporate.colliers.com, Twitter @Colliers or LinkedIn.

For further information please contact:
David Storey
Regional Director, Marketing & Communications | Asia Pacific
Colliers International
Tel: +61 2 9770 3181 or 0416 013 500
Email: david.storey@colliers.com
www.colliers.com.au